Supplementary Figure 2 from Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents

PDF file - 36K, Cells were treated with PTEN siRNA for 48 h, and then treated with PLX4720 at doses near the individual IC50s for a further 72 h. (HT29: 0.01�M, Colo205: 0.05�M, Vaco5: 1 �M). HT29 contains an atypical and poorly characterized mutation (P449T) outside of the hotspots in the kinase and helical domains. siPTEN did not impact PLX4720 sensitivity in Vaco5, which contains a known activating mutation in the helical domain of PIK3CA.